Effects of KR-30035, a novel multidrug-resistance modulator, on the cardiovascular system of rats in vivo and on the cell cycle of human cancer cells in vitro.
The present study was performed to evaluate the adverse effects of KR-30035, a multidrug-resistance modulator, on the cardiovascular system in vivo, along with its effect on paclitaxel-induced cell cycle arrest in cultured cancer cells. In anesthetized rats, KR-30035 was about 10-fold less potent than verapamil in lowering blood pressure (i.v. ED20: 0.320+/-0.052 and 0.034+/-0.005 mg/kg, respectively) and in producing electrocardiogram changes. In conscious spontaneously hypertensive rats, verapamil caused a significant antihypertensive effects at the doses tested (p.o. ED20, 7.8+/-4.0 mg/kg), whereas KR-30035 did not significantly change either the blood pressure or the heart rate at any doses tested (up to 100 mg/kg). The estimated i.v. LD50 values in mice were 5.9 and 48.9 mg/kg for verapamil and KR-30035, respectively. In the presence of 10 microM KR-30035, paclitaxel (1 microM) when added to cultures of HCT15/CL02 human cancer cells greatly shifted the cell population from the G0/G1 phases towards G2/M phases (from 42.4, 30.3 and 27.3 to 14.6, 21.5 and 63.9% for the G0/G1, S and G2/M phases, respectively), with a similar magnitude to that of 10 microM verapamil (14.0, 15.7 and 70.3%, respectively). These results suggest that KR-30035 has weaker in vivo effects on the cardiovascular system compared with verapamil, while potentiating the G2/M arresting effect of paclitaxel on the cell cycle.
Lee
B H
BH
Screening and Toxicology Research Center, Korea Research Institute of Chemical Technology, Yusong, Taejon.
Shin
H S
HS
Lee
C O
CO
Park
S H
SH
Yoo
S E
SE
Yi
K Y
KY
Jung
N P
NP
Choi
S U
SU
D000818:Animals; D000959:Antihypertensive Agents / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use; D002319:Cardiovascular System / Q000187:drug effects* / Q000503:physiopathology; D002453:Cell Cycle / Q000187:drug effects*; D018432:Drug Resistance, Multiple; D004359:Drug Therapy, Combination; D004562:Electrocardiography / Q000187:drug effects; D005434:Flow Cytometry; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D051379:Mice; D051381:Rats; D011918:Rats, Inbred SHR; D017207:Rats, Sprague-Dawley; D013764:Tetrahydronaphthalenes / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D014407:Tumor Cells, Cultured; D014700:Verapamil / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use
D000959:Antihypertensive Agents; D000970:Antineoplastic Agents; D002121:Calcium Channel Blockers; C111621:KR 30035; D013764:Tetrahydronaphthalenes; D014700:Verapamil